Coherus BioSciences (CHRS) Investor Presentation - Slideshow

• Pursue other registration opportunities • TIGIT, ILT4, other combinations Combination therapy provides best opportunity to extend patient survival • Establish toripalimab as SOC in NPC upon approval anticipated in 2023 Platform for Combination Development CIMERLI™ Tracking to the UDENYCA® Success Story Agenda Featured at plenary session External Scientific Validation Progression-Free Survival by BIRC per RECIST v1.1 17 Toripalimab has demonstrated compelling NPC treatment effect; BLA PDUFA Dec 23, 2022 mi ...